6/9/2008 10:31:48 AM
BOTHELL, Wash.--(BUSINESS WIRE)--Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a Phase II clinical trial demonstrating that its ultra rapid acting intranasal insulin was both superior to usual therapy (oral anti-diabetic medicines and/or basal insulin) and non-inferior to insulin aspart (NovoLog®), a rapid-acting injectable insulin, in maintaining glucose control at both 60 and 90 minutes following a meal. The data also demonstrated a statistically significant reduction in the incidence of hypoglycemia (low blood sugar <70 mg/dL) compared with insulin aspart in the four hours following the meal. The data were reported at the 68th Scientific Sessions meeting of the American Diabetes Association in San Francisco in an oral presentation by Professor Lutz Heinemann, Ph.D., of the Profil Institute for Metabolic Research Ltd., and in a Nastech poster presentation.
comments powered by